Posterior uveal melanoma

Summary

Posterior uveal melanoma (MONDO:0003927) is a cancer and 3 clinical trials. Top therapeutic interventions include dacarbazine, sargramostim, and selumetinib. A subtype of uveal melanoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	posterior uveal melanoma
Mondo ID	MONDO:0003927
DOID	DOID:6566
GARD	0023740
Is cancer (heuristic)	yes

Also known as: medium/large size posterior uveal melanoma · small size posterior uveal melanoma

Disease family

This is a subtype of uveal melanoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › sensory system cancer › ocular cancer › uveal cancer › uveal melanoma › posterior uveal melanoma

Related subtypes (7): spindle cell intraocular melanoma, malignant choroid melanoma, mixed cell uveal melanoma, intermediate cell type uveal melanoma, iris melanoma, necrotic uveal melanoma, epithelioid cell uveal melanoma

Subtypes (2): small size posterior uveal melanoma, medium/large size posterior uveal melanoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01989572	PHASE3	COMPLETED	Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery
NCT01143402	PHASE2	COMPLETED	Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye
NCT02336763	Not specified	TERMINATED	Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DACARBAZINE	4	1
SARGRAMOSTIM	4	1
SELUMETINIB	4	1
TYROSINASE	3	1
CHEMBL2369717	0	1
CHEMBL1574179	0	1
CHEMBL4463209	0	1